Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background: Dementia with Lewy bodies (DLB) is a neurodegenerative disease where synaptic loss and reduced synaptic integrity are important neuropathological substrates. Neuronal Pentraxin 2(NPTX2) is a synaptic protein that drives the GABAergic inhibitory circuit. Our aim was to examine if NPTX2 cerebral spinal fluid (CSF) levels in DLB patients were altered and how these levels related to other synaptic protein levels and to cognitive function and decline. Methods: NPTX2, VGF, and α-synuclein levels were determined in CSF of cognitive healthy (n = 27), DLB (n = 48), and AD (n = 20) subjects. Multiple cognitive domains were tested, and data were compared using linear models. Results: Decreased NPTX2 levels were observed in DLB (median = 474) and AD (median = 453) compared to cognitive healthy subjects (median = 773). Strong correlations between NPTX2, VGF, and α-synuclein were observed dependent on diagnosis. Combined, these markers had a high differentiating power between DLB and cognitive healthy subjects (AUC = 0.944). Clinically, NPTX2 levels related to global cognitive function and cognitive decline in the visual spatial domain. Conclusion: NPTX2 CSF levels were reduced in DLB and closely correlated to decreased VGF and α-synuclein CSF levels. CSF NPTX2 levels in DLB related to decreased functioning in the visual spatial domain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This difference might result from PDD and DLB being Lewy body diseases characterized by α-synuclein accumulations, as indicated above [71, 72], while AD and FTD are caused by the accumulation of different proteins leading to distinct pathological mechanisms.”
The cited source says what the claim attributes to it.
In the citing paper
“NPTX2 CSF levels were lower in patients with DLB than in cognitive healthy controls (Boiten et al. 2020).”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Boiten et al. 2020
In the citing paper
“We and others recently showed that decreased NPTX2 levels in DLB correlate with α-synuclein, confirming the possible interaction of α-synuclein aggregates that disturb pre-synaptic functioning when NPTX2 levels are decreased [71, 72].”
In the citing paper
“As for non-AD conditions, NPTX2 correlated with CSF levels of other synaptic proteins such as neurosecretory protein VGF and α-synuclein in DLB (Boiten et al. 2020).”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Boiten et al. 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · cited 3×
“Deviations from relations between biomarkers observed in cognitive healthy subjects might be indicative of disease severity, as is done in AD with the AT(N) norms [13].”
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · cited 1×
“Subjects were labelled as SCD when they presented to the memory clinic with subjective memory complains, yet had an unimpaired performance levels on the cognitive test, and criteria for mild cognitive impairment, AD, or other neurological or psychiatric disorders were not met [40].”
Wang, G., Cui, H.-L., & Huang, Y. (2018) · Neurology · doi:10.1212/wnl.0000000000004918 · Cited by 1,127 · cited 3×
“Cognitive decline in DLB differs from that in AD, since it shows a more pronounced effect on the visual spatial, attention, and executive function domains, in contrast to the predominant effects on the memory domain in AD [7–9].”
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627
Cell Biology and Pathophysiology of α-Synuclein
Burré, J., Sharma, M., & Südhof, T. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024091 · Cited by 579
Kramer, M. L., & Schulz-Schaeffer, W. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4564-06.2007 · Cited by 571
Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product narp.
O’Brien, R. J., Xu, D., Petralia, R. S., Steward, O., Huganir, R. L., & Worley, P. (1999) · Neuron · doi:10.1016/s0896-6273(00)80782-5 · Cited by 471 · cited 1×
“After exocytosis, this complex is able to mediate AMPA receptor, clustering post-synaptically at GABAergic interneurons [20].”
Self-citationOptimizing Patient Care and Research: The Amsterdam Dementia Cohort
van der Flier, W. M., Pijnenburg, Y. A. L., Prins, N., Lemstra, A. W., Bouwman, F. H., Teunissen, C. E., van Berckel, B. N. M., Stam, C. J., Barkhof, F., Visser, P. J., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132306 · Cited by 398 · cited 1×
“In this study, a total of 95 subjects were included from the Amsterdam dementia cohort [39], 27 with subjective cognitive decline (SCD), 48 with DLB, and 20 with AD.”
Self-citationNarp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons
Chang, M. C., Park, J. M., Pelkey, K. A., Grabenstatter, H. L., Xu, D., Linden, D. J., Sutula, T. P., McBain, C. J., & Worley, P. F. (2010) · Nature Neuroscience · doi:10.1038/nn.2621 · Cited by 316
Self-citationNPTX2 and cognitive dysfunction in Alzheimer’s Disease
Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., et al. (2017) · eLife · doi:10.7554/elife.23798 · Cited by 316 · cited 7×
“This makes it a selective marker for the principle neuron–interneuron inhibitory circuit [21].”
InfluentialSelf-citationThe physiological role of α‐synuclein and its relationship to Parkinson’s Disease
Sulzer, D., & Edwards, R. H. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14810 · Cited by 312
Alder, J., Thakker-Varia, S., Bangasser, D. A., Kuroiwa, M., Plummer, M. R., Shors, T. J., & Black, I. B. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10800.2003 · Cited by 302 · cited 2×
“The other candidate biomarker in the DLB proteomics study, VGF, is an interesting marker to compare to NPTX2, as its transcription is induced by neuronal growth factor (NGF) and BDNF [26,27].”
Xu, D., Hopf, C., Reddy, R., Cho, R. W., Guo, L., Lanahan, A., Petralia, R. S., Wenthold, R. J., O'Brien, R. J., & Worley, P. (2003) · Neuron · doi:10.1016/s0896-6273(03)00463-x · Cited by 265 · cited 1×
“NPTX2 forms a complex with two other pentraxins: NPTX1 and NPTXR [19].”
Self-citationWalker, L., McAleese, K. E., Thomas, A. J., Johnson, M., Martin-Ruiz, C., Parker, C., Colloby, S. J., Jellinger, K., & Attems, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1406-3 · Cited by 225 · cited 2×
“Examining the different types of neurodegenerative processes in living individuals is challenging, as multiple pathological processes are concurring in the aging brain leading to comparable clinical presentations [1,2].”
Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201700731r · Cited by 219 · cited 1×
“Previous studies have shown a decreased CSF level of NPTX2 in AD patients, FTD, Down syndrome patients, CSF, and neuronal derived extracellular vesicle of AD patients [21–25].”
Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1–42 Analysis Results
Tijms, B. M., Willemse, E. A. J., Zwan, M. D., Mulder, S. D., Visser, P. J., van Berckel, B. N. M., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.281055 · Cited by 210 · cited 1×
“Levels of A β 1–42 were corrected for the methodological drift occurring over the years [41].”
Self-citationMultiscale causal networks identify VGF as a key regulator of Alzheimer’s disease
Beckmann, N. D., Lin, W.-J., Wang, M., Cohain, A. T., Charney, A. W., Wang, P., Ma, W., Wang, Y.-C., Jiang, C., Audrain, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17405-z · Cited by 172 · cited 4×
“Recently, VGF has been implicated as a master regulator of NPTX2 and BDNF [28], where BDNF itself also functions as regulator of both NPTX2 and VGF [18,26].”
InfluentialClinical and multimodal biomarker correlates of ADNI neuropathological findings
Toledo, J. B., Cairns, N. J., Da, X., Chen, K., Carter, D., Fleisher, A., Householder, E., Ayutyanont, N., Roontiva, A., Bauer, R. J., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-65 · Cited by 165 · cited 1×
“Examining the different types of neurodegenerative processes in living individuals is challenging, as multiple pathological processes are concurring in the aging brain leading to comparable clinical presentations [1,2].”
Sanford, A. M. (2018) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2018.06.007 · Cited by 151
Duits, F. H., Brinkmalm, G., Teunissen, C. E., Brinkmalm, A., Scheltens, P., Van der Flier, W. M., Zetterberg, H., & Blennow, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0335-x · Cited by 137 · cited 1×
“VGF has also been implicated as an AD biomarker and changes in relation to disease progression [28,31].”
Self-citationChiasserini, D., Biscetti, L., Eusebi, P., Salvadori, N., Frattini, G., Simoni, S., De Roeck, N., Tambasco, N., Stoops, E., Vanderstichele, H., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0276-4 · Cited by 134 · cited 1×
“Changes in CSF levels of α -synuclein have been reported in both AD and DLB [35,36], where both increased and decreased levels of α -synuclein have reported in DLB patients CSF [37,38].”
Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133 · cited 2×
“Previously, similar findings relating NPTX2 to cognitive decline had been observed in AD [21,22].”
Self-citationSathe, G., Na, C. H., Renuse, S., Madugundu, A. K., Albert, M., Moghekar, A., & Pandey, A. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800105 · Cited by 126
van Steenoven, I., on behalf of the European DLB consortium, Aarsland, D., Weintraub, D., Londos, E., Blanc, F., van der Flier, W. M., Teunissen, C. E., Mollenhauer, B., Fladby, T., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160322 · Cited by 124 · cited 1×
“Second, in a substantial portion of DLB patients (40–60%), pathological changes of Alzheimer’s disease (AD) are also observed (A β 1–42 aggregation into amyloid plaques and the phosphorylation and aggregation of tau protein) [3].”
Self-citationPossenti, R., Eldridge, J., Paterson, B., Grasso, A., & Levi, A. (1989) · EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08345.x · Cited by 106 · cited 2×
“VGF peptides are stored in dense core vesicles (DCVs), function as secretory peptide at synapses, and are important for a number of neuronal functions [27,29].”
α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
van Steenoven, I., Majbour, N. K., Vaikath, N. N., Berendse, H. W., van der Flier, W. M., van de Berg, W. D. J., Teunissen, C. E., Lemstra, A. W., & El‐Agnaf, O. M. A. (2018) · Movement Disorders · doi:10.1002/mds.111 · Cited by 104
Self-citationα-Synuclein: A Multifunctional Player in Exocytosis, Endocytosis, and Vesicle Recycling
Huang, M., Wang, B., Li, X., Fu, C., Wang, C., & Kang, X. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00028 · Cited by 101 · cited 1×
“VGF and α -synuclein might be mechanistically linked, as VGF is excreted by DCVs and α -synuclein functions in DCV recycling [29,33].”
Lewis, J. E., Brameld, J. M., & Jethwa, P. H. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00003 · Cited by 87 · cited 2×
“VGF peptides are stored in dense core vesicles (DCVs), function as secretory peptide at synapses, and are important for a number of neuronal functions [27,29].”
Khundakar, A. A., Hanson, P. S., Erskine, D., Lax, N. Z., Roscamp, J., Karyka, E., Tsefou, E., Singh, P., Cockell, S. J., Gribben, A., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0334-3 · Cited by 84 · cited 3×
“Interestingly, the GABAergic interneurons of the visual cortex have been implicated in DLB [6], and decline of synaptic functions in this region is also observed in DLB [4].”
van Steenoven, I., Koel-Simmelink, M. J. A., Vergouw, L. J. M., Tijms, B. M., Piersma, S. R., Pham, T. V., Bridel, C., Ferri, G.-L., Cocco, C., Noli, B., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00388-2 · Cited by 83 · cited 1×
“In a recent CSF proteomics study, we identified novel potential DLB biomarkers, including neuronal Pentraxin 2 (NPTX2), VGF (a non-acronym), and secretogranin II (SCGII) [15].”
Self-citationLatest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Milà-Alomà, M., Suárez-Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 78 · cited 1×
“This is illustrated by their use in AD, where abnormal cerebral spinal fluid (CSF) level of A β 1–42, phosphorylated tau and total tau aid diagnosis [13,14] and can be used to outline the disease trajectory [13].”
Hamilton, J. M., Landy, K. M., Salmon, D. P., Hansen, L. A., Masliah, E., & Galasko, D. R. (2011) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31823033bc · Cited by 63
Synaptic Proteins and Choline Acetyltransferase Loss in Visual Cortex in Dementia With Lewy Bodies
Mukaetova-Ladinska, E. B., Andras, A., Milne, J., Abdel-All, Z., Borr, I., Jaros, E., Perry, R. H., Honer, W. G., Cleghorn, A., Doherty, J., et al. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31827c5710 · Cited by 62 · cited 3×
“Interestingly, the GABAergic interneurons of the visual cortex have been implicated in DLB [6], and decline of synaptic functions in this region is also observed in DLB [4].”
α-synuclein induced synapse damage is enhanced by amyloid-β1-42
Bate, C., Gentleman, S., & Williams, A. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-55 · Cited by 59
Mollenhauer, B., Bowman, F. D., Drake, D., Duong, J., Blennow, K., El‐Agnaf, O., Shaw, L. M., Masucci, J., Taylor, P., Umek, R. M., et al. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14569 · Cited by 55 · cited 1×
“For the determination of α -synuclein level, an ELISA from ADx neurosciences (Gent, Belgium), available through Euroimmun, was used [42].”
Self-citationVGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
van Steenoven, I., Noli, B., Cocco, C., Ferri, G., Oeckl, P., Otto, M., Koel‐Simmelink, M. J. A., Bridel, C., van der Flier, W. M., Lemstra, A. W., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194674 · Cited by 47 · cited 3×
“As previously presented, CSF VGF levels were only significantly decreased in DLB and not in AD [30], and the CSF levels of α -synuclein were only increased in the AD group (Supplemental Figure S1).”
InfluentialSelf-citationSoldan, A., Moghekar, A., Walker, K. A., Pettigrew, C., Hou, X., Lu, H., Miller, M. I., Alfini, A., Albert, M., Xu, D., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00132 · Cited by 46 · cited 1×
“In the latter, studies have shown a relation between NPTX2 and hippocampal volume and functional connectivity in the salient/attention networks [21,23].”
Self-citationDefinition of a Bidirectional Activity-Dependent Pathway Involving BDNF and Narp
Mariga, A., Glaser, J., Mathias, L., Xu, D., Xiao, M., Worley, P., Ninan, I., & Chao, M. V. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.064 · Cited by 45 · cited 2×
“Its expression can be induced by neuronal activity and brain derived neurotrophic factor (BDNF) [18].”
Self-citationBelbin, O., Xiao, M.-F., Xu, D., Carmona-Iragui, M., Pegueroles, J., Benejam, B., Videla, L., Fernández, S., Barroeta, I., Nuñez-Llaves, R., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00398-0 · Cited by 39
Self-citationSex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies
Beek, M. H. C. T. V., Mofrad, R. B., van Steenoven, I., Vanderstichele, H., Scheltens, P., Teunissen, C. E., Lemstra, A. W., & van der Flier, W. M. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00610-9 · Cited by 39
Self-citationChatterjee, M., van Steenoven, I., Huisman, E., Oosterveld, L. P., Berendse, H. W., van der Flier, W. M., del Campo, M., Lemstra, A. W., van de Berg, W. D. J., & Teunissen, C. E. (2020) · Biomolecules · doi:10.3390/biom10081177 · Cited by 26 · cited 1×
“Under physiological conditions, many synaptic proteins show close correlations, as seen for neurogranin and SNAP-25 [21], α -synuclein and neurogranin [44], and Contactin 2 and α -synuclein [45].”
Self-citationMavroudis, I. A., Petridis, F., Chatzikonstantinou, S., & Kazis, D. A. (2020) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000381 · Cited by 25 · cited 1×
“Changes in CSF levels of α -synuclein have been reported in both AD and DLB [35,36], where both increased and decreased levels of α -synuclein have reported in DLB patients CSF [37,38].”
Azar, M., Chapman, S., Gu, Y., Leverenz, J. B., Stern, Y., & Cosentino, S. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12120 · Cited by 23 · cited 1×
“Cognitive decline in DLB differs from that in AD, since it shows a more pronounced effect on the visual spatial, attention, and executive function domains, in contrast to the predominant effects on the memory domain in AD [7–9].”
Viodé, A., Epelbaum, S., Benyounes, I., Verny, M., Dubois, B., Junot, C., Fenaille, F., Lamari, F., & Bécher, F. (2019) · The Analyst · doi:10.1039/c9an00751b · Cited by 18
CSF α-synuclein correlates with CSF neurogranin in late-life depression
Bruno, D., Reichert-Plaska, C., Clark, D. P. A., Zetterberg, H., Blennow, K., Verbeek, M., & Pomara, N. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1744596 · Cited by 10
Bonanni, L., Franciotti, R., Pizzi, S. D., Thomas, A., & ONOFRJ, M. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_14 · Cited by 9 · cited 1×
“In areas related to these domains, synaptic dysfunction might play an essential role in this clinical presentation [10].”
Cited by
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112
Brockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01276-6 · Cited by 138
Nilsson, J., Binette, A. P., Palmqvist, S., Brum, W. S., Janelidze, S., Ashton, N. J., Spotorno, N., Stomrud, E., Gobom, J., Zetterberg, H., et al. (2024) · Brain · doi:10.1093/brain/awae032 · Cited by 92
“…lower CSF concentrations of the pentraxins in AD 38,42,53-57 as well as in other neurodegenerative diseases such as atypical parkinsonism, 39 DLB 38,58,59 and FTLD. 38,59,60 In a previous study, lower levels of NPTX2 were also observed in PD compared with controls; the re-sults were not replicated…”
ResultNilsson, J., Cousins, K. A. Q., Gobom, J., Portelius, E., Chen‐Plotkin, A. S., Shaw, L. M. J., Grossman, M., Irwin, D. J., Trojanowski, J. Q., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12809 · Cited by 65
Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer’s Disease
Bousiges, O., & Blanc, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126371 · Cited by 68
Metadata
- Authors
- Boiten, W., van Steenoven, I., Xiao, M.-F., Worley, P., Noli, B., Cocco, C., Ferri, G.-L., Lemstra, A., & Teunissen, C.
- Affiliations
- Amsterdam University Medical Centers (NL)
- Johns Hopkins University (US)
- University of Cagliari (IT)
- Corresponding author
- Boiten, Walter
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-12-29
- Volume
- 10
- Issue
- 1
- Pages
- 38
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7824459
- OpenAlex
- W3117487831
- Cited by
- 42
- References
- 42
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 7 · 2023: 4 · 2022: 9 · 2021: 10
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-12-29)
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- ZonMw (733050509, 733050102)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- dementia with Lewy bodies, NPTX2, alpha-synuclein, VGF, cerebrospinal fluid biomarkers, synaptic loss, Alzheimer's disease, cognitive decline, visuospatial ability, GABAergic inhibition
- MeSH terms
- Pentraxins, Aged, C-Reactive Protein, Female, Humans, Male, Middle Aged, Nerve Growth Factors, Nerve Tissue Proteins, Cohort Studies, Biomarkers, Case-Control Studies, Lewy Body Disease, alpha-Synuclein, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.